logo-loader
HealthPharma & Biotech
MaxCyte

MaxCyte shows off CARMA platform at industry conference in Washington DC

One of CARMA’s key differentiators is that it can be used to manufacture drug candidates within a single day, providing a “meaningful reduction” in wait times for patients

cancer cell
A phase I study of MaxCyte’s first CARMA drug, MCY-M11, is underway in ovarian cancer patients

MaxCyte Inc (LON:MXCT) has been showing off its CARMA cell therapy platform at an industry conference in Washington DC.

Earlier this week, MaxCyte’s director of technical operations, Robert Keefe, gave a speech at the American Society of Gene and Cell Therapy.

LOOK: Scroll to page 40 to see Keefe’s presentation

He highlighted the potential to manufacture drug candidates on the platform within a day, providing a much-needed faster turnaround of autologous cell therapy to patients.

Keefe also discussed the manufacturing feasibility data for MaxCyte’s first CARMA drug candidate, MCY-M11, which is currently undergoing a phase I study in 15 women with ovarian cancer and peritoneal mesothelioma.

“The advancement of our first CARMA clinical trial, which is consistently showing the feasibility of our rapid manufacturing process, is significant for MaxCyte and the application of our technology,” said chief medical officer Claudio Dansky Ullmann.

“Development of a cell therapy with application in solid tumours is impactful for patients with unmet needs in a variety of cancers and we look forward to further advancing this program.”

Quick facts: MaxCyte

Price: £1.20

Market: AIM
Market Cap: £68.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read